Roche Unveils Higher-Throughput Cobas Systems as it Maps out MDx Strategy | GenomeWeb

Roche Molecular Systems this week unveiled the blueprint for its future molecular diagnostics strategy, providing attendees of the EuroMedLab conference in Milan, Italy, with a preview of its next two large-scale MDx systems.

Specifically, Roche introduced the Cobas 6800 and Cobas 8800 — essentially high- and very-high-throughput versions of the company's Cobas 4800 platform, which is already commercially available along with several US Food and Drug Administration-approved molecular assays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.